AstraZeneca plans to invest $133 million in its Australian manufacturing site as demand for its respiratory medicines in China has grown. The company plans to expand its facility in Sydney suburb North Ryde, New South Wales, which will create 250 new jobs and increase the site’s annual exports to AU$4.4 billion over the next four years. This expansion follows the company’s $67 million investment in 2017 to grow the site.

AstraZeneca employs more than 1,000 people in Australia and New Zealand. The company also has an on-site commercial organization that spans corporate affairs, distribution, finance, and marketing. The Sydney site delivers medicines to Australia, Asia-Pacific countries and other markets globally.